Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model

被引：45

作者：

Chandrasekar, PH ^{[1
]}

Cutright, J ^{[1
]}

Manavathu, E ^{[1
]}

机构：

[1] Wayne State Univ, Sch Med, Dept Internal Med, Div Infect Dis, Detroit, MI 48201 USA

来源：

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2000年 / 45卷 / 05期

关键词：

D O I：

10.1093/jac/45.5.673

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

We compared the efficacies of amphotericin B and voriconazole against invasive pulmonary aspergillosis in a guinea-pig model. A susceptible isolate of Aspergillus fumigatus was used to produce the infection. Voriconazole-treated animals had significantly better survival and decreased fungal burden in the lungs as compared with controls. Although no statistical difference was seen between the efficacies of voriconazole and amphotericin B, a trend favouring voriconazole was noted. Thus, voriconazole, with its cidal activity, may be an attractive alternative to potentially toxic amphotericin B in the treatment of invasive pulmonary aspergillosis.

引用

页码：673 / 676

页数：4

共 18 条

[1] In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole, and amphotericin B [J].

Abraham, OC ;

Manavathu, EK ;

Cutright, JL ;

Chandrasekar, PH .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1999, 33 (01) :7-11

[2] In vitro studies of two triazole antifungal agents (Voriconazole [UK-109,496] and fluconazole) against Candida species [J].

Barry, AL ;

Brown, SD .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (08) :1948-1949

[3] FUNGAL-INFECTIONS IN CANCER-PATIENTS - AN INTERNATIONAL AUTOPSY SURVEY [J].

BODEY, G ;

BUELTMANN, B ;

DUGUID, W ;

GIBBS, D ;

HANAK, H ;

HOTCHI, M ;

MALL, G ;

MARTINO, P ;

MEUNIER, F ;

MILLIKEN, S ;

NAOE, S ;

OKUDAIRA, M ;

SCEVOLA, D ;

VANTWOUT, J .

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1992, 11 (02) :99-109

[4]

Bowden R, 1998, 10 INT S INF IMM HOS

[5] NIAID MYCOSES STUDY-GROUP MULTICENTER TRIAL OF ORAL ITRACONAZOLE THERAPY FOR INVASIVE ASPERGILLOSIS [J].

DENNING, DW ;

LEE, JY ;

HOSTETLER, JS ;

PAPPAS, P ;

KAUFFMAN, CA ;

DEWSNUP, DH ;

GALGIANI, JN ;

GRAYBILL, JR ;

SUGAR, AM ;

CATANZARO, A ;

GALLIS, H ;

PERFECT, JR ;

DOCKERY, B ;

DISMUKES, WE ;

STEVENS, DA .

AMERICAN JOURNAL OF MEDICINE, 1994, 97 (02) :135-144

[6] Therapeutic outcome in invasive aspergillosis [J].

Denning, DW .

CLINICAL INFECTIOUS DISEASES, 1996, 23 (03) :608-615

[7] In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens [J].

Espinel-Ingroff, A .

JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (01) :198-202

[8] Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis [J].

George, D ;

Miniter, P ;

Andriole, VT .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (01) :86-91

[9]

JEZEQUEL SG, 1995, 35 INT C ANT AG CHEM, P126

[10] A comparative study of the broth micro- and macro-dilution techniques for the determination of the in vitro susceptibility of Aspergillus fumigatus [J].

Manavathu, EK ;

Alangaden, GJ ;

Lerner, SA .

CANADIAN JOURNAL OF MICROBIOLOGY, 1996, 42 (09) :960-964

← 1 2 →